Ionis Pharmaceuticals annual current ratio
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ionis Pharmaceuticals Current Ratio Growth & History (IONS)
Ionis Pharmaceuticals's current ratio was 3.83 for fiscal 2025.
View full Ionis Pharmaceuticals company overviewIonis Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 3.83 | −4.64 | −54.83% |
| 2024 | 2024-12-31 | 8.47 | 2.58 | +43.68% |
| 2023 | 2023-12-31 | 5.90 | −1.17 | −16.61% |
| 2022 | 2022-12-31 | 7.07 | −2.68 | −27.48% |
| 2021 | 2021-12-31 | 9.75 | 6.19 | +174.02% |
| 2020 | 2020-12-31 | 3.56 | −6.41 | −64.30% |
| 2019 | 2019-12-31 | 9.97 | 2.09 | +26.51% |
| 2018 | 2018-12-31 | 7.88 | 3.08 | +64.19% |
| 2017 | 2017-12-31 | 4.80 | −1.17 | −19.56% |
| 2016 | 2016-12-31 | 5.96 | 0.34 | +6.09% |
| 2015 | 2015-12-31 | 5.62 | −1.63 | −22.49% |
| 2014 | 2014-12-31 | 7.25 | −0.27 | −3.53% |
| 2013 | 2013-12-31 | 7.52 | 1.82 | +31.98% |
| 2012 | 2012-12-31 | 5.70 | 0.97 | +20.41% |
| 2011 | 2011-12-31 | 4.73 | 0.17 | +3.71% |
| 2010 | 2010-12-31 | 4.56 | −0.79 | −14.70% |
| 2009 | 2009-12-31 | 5.35 | — | — |
Ionis Pharmaceuticals quarterly current ratio
Q4.09
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 7.89 | 5.02 | +174.79% |
| Q1 2026 | 2026-03-31 | 4.10 | −5.57 | −57.59% |
| Q4 2025 | 2025-12-31 | 3.83 | −4.64 | −54.83% |
| Q3 2025 | 2025-09-30 | 2.79 | −6.12 | −68.71% |
| Q2 2025 | 2025-06-30 | 2.87 | −4.74 | −62.25% |
| Q1 2025 | 2025-03-31 | 9.66 | 2.29 | +31.08% |
| Q4 2024 | 2024-12-31 | 8.47 | 2.58 | +43.68% |
| Q3 2024 | 2024-09-30 | 8.91 | 2.52 | +39.35% |
| Q2 2024 | 2024-06-30 | 7.61 | −1.48 | −16.27% |
| Q1 2024 | 2024-03-31 | 7.37 | −2.44 | −24.83% |
| Q4 2023 | 2023-12-31 | 5.90 | −1.17 | −16.61% |
| Q3 2023 | 2023-09-30 | 6.39 | −1.20 | −15.78% |
| Q2 2023 | 2023-06-30 | 9.09 | 0.91 | +11.06% |
| Q1 2023 | 2023-03-31 | 9.81 | −0.05 | −0.55% |
| Q4 2022 | 2022-12-31 | 7.07 | −2.68 | −27.48% |
| Q3 2022 | 2022-09-30 | 7.59 | −0.11 | −1.46% |
| Q2 2022 | 2022-06-30 | 8.18 | 0.56 | +7.40% |
| Q1 2022 | 2022-03-31 | 9.86 | 3.12 | +46.30% |
| Q4 2021 | 2021-12-31 | 9.75 | 6.19 | +174.02% |
| Q3 2021 | 2021-09-30 | 7.71 | −2.67 | −25.72% |
| Q2 2021 | 2021-06-30 | 7.62 | −3.32 | −30.37% |
| Q1 2021 | 2021-03-31 | 6.74 | −3.17 | −32.00% |
| Q4 2020 | 2020-12-31 | 3.56 | −6.41 | −64.30% |
| Q3 2020 | 2020-09-30 | 10.37 | −0.02 | −0.16% |
| Q2 2020 | 2020-06-30 | 10.94 | 0.93 | +9.32% |
| Q1 2020 | 2020-03-31 | 9.91 | 0.51 | +5.44% |
| Q4 2019 | 2019-12-31 | 9.97 | 2.09 | +26.51% |
| Q3 2019 | 2019-09-30 | 10.39 | 2.40 | +30.04% |
| Q2 2019 | 2019-06-30 | 10.01 | 1.63 | +19.44% |
| Q1 2019 | 2019-03-31 | 9.40 | 4.03 | +74.89% |
| Q4 2018 | 2018-12-31 | 7.88 | 3.08 | +64.19% |
| Q3 2018 | 2018-09-30 | 7.99 | 1.74 | +27.74% |
| Q2 2018 | 2018-06-30 | 8.38 | 3.35 | +66.62% |
| Q1 2018 | 2018-03-31 | 5.38 | −0.27 | −4.70% |
| Q4 2017 | 2017-12-31 | 4.80 | −1.17 | −19.56% |
| Q3 2017 | 2017-09-30 | 6.25 | −0.58 | −8.46% |
| Q2 2017 | 2017-06-30 | 5.03 | −1.25 | −19.96% |
| Q1 2017 | 2017-03-31 | 5.64 | −0.49 | −8.06% |
| Q4 2016 | 2016-12-31 | 5.96 | 0.34 | +6.09% |
| Q3 2016 | 2016-09-30 | 6.83 | −0.27 | −3.84% |
| Q2 2016 | 2016-06-30 | 6.28 | −2.09 | −24.98% |
| Q1 2016 | 2016-03-31 | 6.14 | −2.19 | −26.34% |
| Q4 2015 | 2015-12-31 | 5.62 | −1.63 | −22.49% |
| Q3 2015 | 2015-09-30 | 7.11 | 0.76 | +11.95% |
| Q2 2015 | 2015-06-30 | 8.38 | 1.38 | +19.64% |
| Q1 2015 | 2015-03-31 | 8.33 | 1.17 | +16.33% |
| Q4 2014 | 2014-12-31 | 7.25 | −0.27 | −3.53% |
| Q3 2014 | 2014-09-30 | 6.35 | −1.04 | −14.13% |
| Q2 2014 | 2014-06-30 | 7.00 | −0.69 | −8.97% |
| Q1 2014 | 2014-03-31 | 7.16 | 1.02 | +16.56% |
| Q4 2013 | 2013-12-31 | 7.52 | 1.82 | +31.98% |
| Q3 2013 | 2013-09-30 | 7.39 | 0.38 | +5.47% |
| Q2 2013 | 2013-06-30 | 7.69 | 1.33 | +20.85% |
| Q1 2013 | 2013-03-31 | 6.14 | 0.51 | +9.05% |
| Q4 2012 | 2012-12-31 | 5.70 | 0.97 | +20.41% |
| Q3 2012 | 2012-09-30 | 7.01 | 2.49 | +55.24% |
| Q2 2012 | 2012-06-30 | 6.36 | 1.90 | +42.52% |
| Q1 2012 | 2012-03-31 | 5.63 | 1.00 | +21.58% |
| Q4 2011 | 2011-12-31 | 4.73 | 0.17 | +3.71% |
| Q3 2011 | 2011-09-30 | 4.51 | −0.52 | −10.25% |
| Q2 2011 | 2011-06-30 | 4.47 | −0.64 | −12.49% |
| Q1 2011 | 2011-03-31 | 4.63 | — | — |
| Q4 2010 | 2010-12-31 | 4.56 | −0.79 | −14.70% |
| Q3 2010 | 2010-09-30 | 5.03 | — | — |
| Q2 2010 | 2010-06-30 | 5.10 | — | — |
| Q4 2009 | 2009-12-31 | 5.35 | — | — |
Ionis Pharmaceuticals current ratio trends
Over the last five fiscal years, Ionis Pharmaceuticals's current ratio increased from 3.56 to 3.83, a change of 0.27. The latest reported quarter, Q2 2026, shows 7.89.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ionis Pharmaceuticals source filings ↗Community posts
Roche quantifies proteinuria reduction for Ionis-licensed sefaxersen
Ionis ($IONS) reported new detailed results from partner Roche’s Phase 3 IMAgINATION trial of sefaxersen in IgA nephropathy. The investigational monthly injection reduced urine protein-to-creatinine ratio by 43.1% versus placebo at 37 weeks ...
